On March 4, 2011, the FDA Released a Topamax Warning Citing High Risk of Cleft Palate Birth Defects. Today, the Law Firm Anapol Schwartz Launches Online Resources for Women and Expecting Mothers.
In repsonse to the Food and Drug Administration (FDA) issuing a news release warning the public about an increased risk of cleft palate and lip palate oral birth defects for infants born to mothers who have taken the antiepileptic drug Topamax (topiramate) and its generic forms, Anapol Schwartz now offers public access to FDA Topamax adverse event data, This resource provides a list of reports on a case by case detailed basis, thus serving as research tool for those concerned about Topamax cleft palate risks.
The online resource address the fact that Topamax is prescribed to treat specific kinds of seizures for people with epilepsy and is also used to prevent migraine headaches. The resources also emphasize that a person taking Topamax should not suddenly stop taking the drug, even if pregnant, until discussing the matter with a health care professional. Serious problems can be caused by immediately stopping Topamax intake. In addition, failing to treat epilepsy during pregnancy can be dangerous for a woman and her developing baby.
See: The full press release here.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.